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Abstract Hepatocyte paraffin 1 (Hep Par 1) and neprilysin
(CD10) are well-known markers of hepatocellular carci-
noma (HCC). To assess their potential prognostic role, we
conducted a retrospective analysis of 97 formalin-fixed and
paraffin-embedded HCC from patients treated by surgery
with curative intent, using standard immunohistochemical
procedures and semiquantitative analysis. Strong Hep Par 1
expression and canalicular CD10 staining pattern were
significantly correlated with smaller tumor size (p=0.007
and 0.04, respectively). On univariate analysis, longer
overall survival was observed in patients with strong Hep
Par 1 expression (p=0.0005) and in patients with a
CD10can staining pattern (p=0.02). On multivariate anal-
ysis, the combined immunohistochemical score (CIS)
obtained by addition of Hep Par 1 and CD10can scores
and subtraction of cytoplasmic CD10 score was retained as
the single most important prognostic factor (p=0.001).
Patients with a CIS <4 had a 3.5-fold increased risk of
death, as compared to those with a CIS ≥4. In conclusion,
strong Hep Par 1 expression, presence of CD10can
labeling, and absence of CD10cyt staining are favorable
prognostic factors in HCC, which can be easily combined
into a single immunohistochemical score for routine
clinical use.
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Prognosis
Introduction
Prognosis of hepatocellular carcinoma (HCC) after hepatic
resection with curative intent remains very poor despite
improved surgical techniques [17, 23, 26]. In addition, in
low endemic areas like Switzerland, HCC is often dis-
covered in elderly patients with a long-standing alcoholic
cirrhosis and at high operative risk. Therefore, adequate
prognostic stratification of the patients to guide the clini-
cian in treatment choice is essential. The most important
histopathologic prognostic factors are tumor size, vascular
invasion, tumor multifocality, and tumor grade [1, 24, 29,
30]. Combined scores based on histological features or
image analysis have also been proposed [23]. In addition,
the prognostic significance of a variety of gene products
related to the cell cycle or to cell adhesion has been de-
scribed in the literature, such as the tumor-suppressor gene
p53, the cell cycle inhibitors p21, p27, and cyclin D, and
the cell adhesion molecule beta-catenin [18, 20, 31]. How-
ever, none of these markers have found their way into
routine clinical use.
Hepatocyte paraffin 1 (Hep Par 1) [2, 21, 27, 38] and
neprilysin (CD10 or CALLA) [5, 40] are well-established
markers of HCC, and their use as diagnostic aid is well
documented in the literature. Hep Par 1 has been obtained
by immunizing mice with a crude antigen extracted from
human liver tissue [38]. It reacts with a hepatocyte-specific
epitope of the mitochondrial membrane [21, 22, 38], re-
sulting in a granular cytoplasmic staining pattern. This
marker has been shown to be highly specific for normal and
neoplastic liver tissue. CD10 is a zinc-dependant cell mem-
brane metallopeptidase, which participates in the postsecre-
tory processing of neuropeptidases and peptide hormones
[37]. In the past, it has been widely used as a marker of
lymphoblasts in acute lymphoblastic leukemia [4]. More
recently, it has also been shown that CD10 is expressed on
the canalicular domain of the cell membrane in normal and
neoplastic liver tissue [7, 11, 12].
Specificity of these two markers has been well estab-
lished in the literature, allowing the distinction of HCC
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from cholangiocarcinomas and carcinoma metastases to the
liver [25, 27, 28]. Surprisingly, to our knowledge, despite
several studies on the diagnostic value of these markers and
their association with tumor grade and growth pattern, the
possible association of their expression with survival has
never been examined in detail. In reviewing our pilot series
of HCC, the extent of Hep Par 1 and canalicular CD10
(CD10can) expression seemed to be related to the degree of
differentiation. In contrast, cytoplasmic CD10 (CD10cyt)
expression seemed to be restricted to cases with low Hep
Par 1 and CD10can expression. We therefore decided to
systematically evaluate the prognostic value of these three
parameters. In the current retrospective study, we analyze
the immunohistochemical expression of Hep Par 1 and
CD10 in formalin-fixed and paraffin-embedded HCC
tissue from patients who underwent either partial hepatec-
tomy with curative intent or total hepatectomy followed by
liver transplantation to assess their prognostic value.
Patients and methods
Patients and tissue samples
All patients (n=122) who underwent either partial hepa-
tectomy with curative intent or total hepatectomy with liver
transplantation because of primary HCC and who were
diagnosed at the Institute of Pathology in Lausanne, Swit-
zerland, between January 1992 and May 2001 were se-
lected for this retrospective study. Excluded were patients
with mixed hepato-choloangiocarcinoma (n=8), fibrolamel-
lar carcinoma (n=1), inadequate follow-up (n=11), missing
material for immunohistochemistry (n=2), and patients who
died within 30 days after diagnosis (n=3). The ethics com-
mittee of our institution approved the study protocol.
The remaining 97 patients consisted of typical Western
European patients whose clinical characteristics were sim-
ilar to those of several other published series [9, 26, 32].
Treatment was partial liver resection in 72 patients (74%)
and total hepatectomy followed by liver transplantation in
25 patients (26%). Most patients (78%) were men. The
median age was 63 years (range 14 to 89 years) and was
similar for male and female patients. Cirrhosis was found in
67 patients (69%). Serology was positive for hepatitis B
virus surface antigen in 10 patients (10%) and hepatitis C
virus antigen in 18 patients (19%). Preoperative aspartate
aminotransferase, alanine aminotransferase, gamma gluta-
myl transferase, and alpha-fetoprotein (AFP) levels were
also recorded. Overall survival time was calculated from
date of diagnosis to date of death or date of last follow-up
until closure of the study which was chosen at 30 August
2002. Intermediate outcomes were not considered. Median
follow-up time computed according the Kaplan–Meier
estimate of potential follow-up was 47 months. Overall
median survival time was 28 months in the whole cohort
and 23 months in the subgroup of patients treated with
partial hepatectomy.
All specimens were fixed in 10% buffered formalin and
embedded in paraffin according to standard histological
practice. All available hematoxylin/eosin-stained sections
(mean 3, range 1 to 12) were reviewed by two experienced
pathologists (D.M. and C.F.), and a representative paraffin
block containing both carcinoma and nontumorous tissue
was selected for immunohistochemistry. Tumor stage was
determined using the International Union against Cancer’s
tumor–nodes–metastasis (TNM) classification of malig-
nant tumors [34]. Because of small sample size, stages pT1
and pT2 were grouped together. Tumors were divided into
grades 1, 2, 3, and 4 according to Edmondson and Steiner
[13]. In the case of a heterogeneous tumor, the highest
grade was retained for the database. Classification of tumor
architecture into trabecular, acinar, compact, and scirrhous
growth pattern was performed according to the World
Health Organization’s criteria [16]. Because of relatively
low numbers of tumors in the various non-trabecular cat-
egories, they were grouped together for statistical analysis.
Tumor size, tumor multifocality (solitary nodules/multiple
nodules), and microvascular invasion (MVI) were also
recorded. Hepatocellular Prognostic Index (HPI) was com-
puted according to Lauwers et al. [23], using the following
formula: HPI = (MVI status × 0.459) + (nuclear grade ×
0.287). Two prognostic groups were derived from this index:
HPI-low (HPI≤0.746), corresponding to patients with
rather good prognosis according to Lauwers et al. [23],
and HPI-high (HPI>0.746), corresponding to patients with
poor prognosis.
With regard to tumor stage, 33 patients (34%) had stages
I and II disease, 29 (30%) had stage III, and 35 had (36%)
stage IV. Most HCC were less than 5 cm in size (n=58,
60%), solitary (n=54, 56%), and with a trabecular archi-
tecture (n=75, 77%). The tumor differentiation was grade 1
in 15 HCC (15%), grade 2 in 47 (48%), grade 3 in 27
(28%), and grade 4 in 8 (8%). MVI was present in 35 HCC
(36%). HPI was high in 51 tumors (53%).
Immunohistochemistry
Immunohistochemistry was performed with mouse mono-
clonal antibodies directed against Hep Par 1 (clone OCH1E5,
DAKO) and CD10 (clone 56C6, Novocastra) using the
streptavidin biotin complex (ABC) method. In brief, 3–4 μ
tissue sections were mounted on aminopropylmethoxysi-
lane-coated slides, deparaffinized in xylene, and rehydrated
in a graded alcohol series. Endogenous peroxidase was
blocked with 1% H2O2 in methanol for 30 min at room
temperature. Antigen retrieval was performed by boiling
the sections (microwave) in 10 mM citrate buffer pH 6.0
for 15 min (Hep Par 1) or 1 mM in EDTA pH 7.5 for 15 min
(CD10). After conditioning with normal horse serum at a
1:30 dilution for 5 min, the sections were incubated either
with anti-Hep Par 1 at a 1:10 dilution for 1 h or with anti-
CD10 at a 1:20 dilution overnight. Detection was per-
formed using biotinylated anti-mouse IgG at a 1:200
dilution and peroxidase-conjugated ABC complex (both
from Vector Laboratories) according to the manufacturer’s
specifications. Between all steps, sections were washed in
Tris-buffered saline. Peroxidase activity was revealed with
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3,3-diaminobenzidine-tetrahydrochloride as chromogen, and
sections were counterstained with Mayer’s hematoxylin.
Primary antibodies were omitted as a negative control.
Nontumorous liver tissue adjacent to HCC and present on
the same slide was used as positive control.
The immunohistochemical Hep Par 1 and CD10 staining
of all slides was evaluated independently by two observers
(D.M. and W.K.F.S) in a blinded manner. Divergent scor-
ings were discussed until a consensus was reached. To
assess reproducibility, a subset of slides was analyzed by a
third pathologist (F.T.B.), who had not done the initial
evaluation based on the information contained in this
manuscript without additional training. Individual tumor
cells were considered to be positive for Hep Par 1 when
their cytoplasmic staining intensity was similar or stronger
than that of the adjacent nontumorous hepatocytes. CD10cyt
staining was considered to be positive in tumor cells when
the cytoplasm showed unambigous labeling in contrast to
the preexisting hepatocytes which were negative. Positive
CD10can staining was defined as crisp focal labeling of the
canalicular aspects of the tumor cell membrane when its
intensity was similar or stronger than that of the non-
tumorous canaliculi.
Based on the percentage of positive cells, Hep Par 1,
CD10can, and CD10cyt immunolabelings were semiquan-
titatively classified into four groups, based on a priori
determined cutoff points. In the first group, less than 5% of
the tumor cells were positive (score 0); in the second group,
5 to 30% of the tumor was positive (score 1); in the third
group, 30 to 90% of the tumor cells were positive (score 2);
and in the last group, more than 90% of the tumor was
positive (score 3).
A combined immunohistochemical score (CIS) was
computed as follows: CIS = Hep Par 1 score + CD10can
score − CD10cyt score.
Statistical analysis
Correlation tests between immunohistochemical and clin-
icopathological parameters were performed using either
Kruskal–Wallis tests (for continuous or ordered variables
such as age, HPI, or tumor grade) or Chi-squared tests (for
categorical variables), unless there was concern regarding
an inadequate number of observations, in which case, a
Fisher’s exact test was used [3].
Overall interobserver agreement was compared using
kappa statistics. According to common usage, kappa values
of ≤0.5 were considered “poor”, 0.51–0.6 “moderate”,
0.61–0.8 “good”, and >0.8 “excellent”.
For Fisher’s exact tests and survival analysis, clinico-
pathological and immunohistochemical variables were di-
chotomized into groups of similar size as follows: age <65 vs.
≥65 years, tumor size ≤5 vs. >5 cm, HPI ≤0.746 (low) vs.
>0.746 (high), Hep Par 1<3 vs. =3, CD10can <2 vs. ≥2,
CD10cyt <1 vs. ≥1, and CIS <4 vs. ≥4.
Survival percentages over time were calculated by
the Kaplan–Meier method [19], and their corresponding
standard errors were determined using the formula of
Greenwood [15]. Univariate associations between the po-
tential prognostic factors and overall survival were tested
using the log-rank test.
Prognostic variables which had been at least marginally
significant in univariate analysis (log-rank test <0.1) were
further analyzed in various Cox regression models using
backward selection with p<0.05 as the exit criterion.
Given the relatively small number of outcome events,
several distinct Cox regression models with a limited
number of covariates had to be evaluated [6].
Estimated hazard ratios of death, with respect to the
indicated reference group, their 95% confidence intervals
(CI), and p values were calculated with appropriate binary
variables to identify each group of interest [10]. Values of
hazard ratios greater than unity indicated increased rates of
death with respect to the chosen reference category.
To evaluate the impact of type of surgery, univariate and
multivariate analysis were done on the whole study pop-
ulation as well as on the subgroup of patients with partial
liver resection.
Statistical analyses were carried out by means of the
software packages Stata, S-plus 2000, and SPSS.
All probability values were evaluated by two-sided tests,
and differences were considered to be significant if the
p value was less than 0.05.
Results
Correlation of Hep Par 1 and CD10 immunolabeling
with clinicopathological features
Hep Par 1 resulted in a diffuse labeling of the cytoplasm of
nontumorous hepatocytes, which served as internal posi-
tive control, with a distinctive granular pattern. It was in-
dependent of the underlying liver pathology, and there was
no staining difference between cirrhotic and non-cirrhotic
liver tissue. Most HCC showed a similar cytoplasmic
labeling, albeit at a highly variable intensity (Fig. 1a–c).
Hep Par 1 expression, evaluated semiquantitatively as
outlined in “Patients and methods”, was extensive (score 3)
in 54 (55%) HCC, partial (score 2) in 31 (32%) HCC, and
focal or absent (score 1 or 0) in 13 (13%) HCC.
CD10 labeled in nontumorous liver exclusively the
luminal portion of bile canaliculi of the hepatocytes as well
as the luminal surface of the bile duct epithelium. There
was no staining difference between cirrhotic and non-
cirrhotic liver. In HCC, a similar canalicular staining pat-
tern was seen forming sharp branching lines which were
typically located between cells and not within them
(Fig. 1d–f). CD10can labeling was widespread (score 3)
in 20 (21%) HCC, partial (score 2) in 38 (39%) HCC, focal
(score 1) in 11 (11%) HCC, and completely absent in 28
(29%) HCC. In addition, some HCC displayed a CD10cyt
labeling (Fig. 1g,h), and very few tumors exhibited a
diffuse cell membrane staining. This type of staining was
not seen in nontumorous hepatocytes. CD10cyt staining
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was extensive (score 3) in 5 (5%) HCC, partial (score 2) in
23 (24%) HCC, focal (score 1) in 18 (19%) HCC, and
absent in 51 (52%) HCC.
Correlations between immunohistochemical features and
histopathologic parameters are reported in detail in Table 1.
High levels of Hep Par 1 expression (score=3) were sig-
nificantly correlated with small tumor size (p=0.007), ab-
sence of MVI (p=0.03), and low HPI (p=0.04). In addition,
Hep Par 1 expression decreased with increasing tumor
grade in a significant manner (p=0.01; Fig. 2a). All other
parameters, including International Union Against Cancer
tumor stage and tumor pattern, lacked any significant cor-
relation with Hep Par 1 score. Extensive CD10can labeling
(score≥2) was more frequent in small HCC (p=0.04) and
male patients (p=0.01). Like Hep Par 1, CD10can expres-
sion was reduced in poorly differentiated tumors (p=0.03;
Fig. 2b). CD10cyt staining was not correlated with any
clinicopathological feature. A high CIS (≥4) showed a
highly significant correlation with reduced tumor size
(p=0.05), and it was also more frequently observed in male
patients (p=0.04). Furthermore, CIS decreased with
decreasing tumor differentiation (p=0.05; Fig. 2c).
To assess reproducibility, a subset of immunolabelings
was reviewed by another pathologist without particular
training. The interobserver agreement was excellent for
Hep Par 1 and CD10can labeling (κ=0.87) and moderate
for CD10cyt labeling (κ=0.53).
Correlation of Hep Par 1 and CD10 expression
with survival by univariate analysis
To determine the prognostic value of Hep Par 1 and CD10
labeling, the immunohistochemical scores were analyzed
as categorical variables using cutoff points that were
chosen in a manner to split the study population in two
Fig. 1 Representative examples
of immunohistochemical stain-
ing in HCC for Hep Par 1 (a–c)
and CD10 (d–h): individual
tumor cells (tu) are considered
positive for Hep Par 1 when
their cytoplasmic immunolabel-
ing is similar to that of adjacent
nontumorous hepatocytes (n).
CD10 labeling is considered to
be canalicular (d–f) when there
is a crisp linear staining between
adjacent tumor cells (inset, d).
CD10cyt staining is considered
significant if individual tumor
cells show an unambigous cy-
toplasmic staining in contrast to
surrounding nontumorous liver
tissue which is negative (g–h).
Scoring is based on the percent-
age of positive tumor cells:
score 3, more than 90% labeled
tumor cells (a, d, and g); score
2, between 30 and 90% (b, e,
and h); and score 1, less than
30% positive tumor cells (c and
f). Scale bars 100 μm
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groups of similar size. To detect a possible bias resulting
from the type of surgery, univariate and multivariate
survival analyses were done not only on the whole study
population but also on the subgroup of patients with partial
liver resection. On univariate analysis (Table 2) of the
whole cohort, Hep Par 1 expression and CD10can labeling
were significantly associated with overall survival (p=0.0005
and 0.02, respectively). Indeed, median survival time of
patients with tumors showing a strong Hep Par 1 staining
(score=3) was more than 100 months in contrast to patients
with a score of <3 who survived only 15 months (Fig. 3a).
Similarly, survival of patients with an at least moderate
CD10can staining (score ≥2) was 54 months in contrast to
17 months for the other patients (Fig. 3b). Similar results
were found in the subgroup of patients with partial liver
resection, who showed also a significant association of
strong Hep Par 1 staining with longer median overall
survival (33 vs. 14 months, p=0.03). There was a trend
toward better overall survival among patients with a
CD10can score of ≥2 (28 vs. 16 months, p=0.09). In contrast,
Table 1 Relationship between expression of Hep Par 1 or CD10 and pathological factors
Number of patients with
Factor Total number
of patients
Hep Par 1
score =3
p valuesa CD10 canalicular
score ≥2
p values CD10 cytoplasmic
score ≥1
p values CISb ≥4 p values
Tumor size (cm)
≤5 58 39 (67%)c 0.007 40 (70%) 0.04 20 (51%) NS 29 (50%) 0.005
>5 39 15 (39%) 18 (46%) 26 (45%) 8 (21%)
MVI
Absent 62 40 (65%) 0.03 37 (60%) NS 29 (47%) NS 26 (42%) NS
Present 35 14 (40%) 21 (60%) 17 (49%) 11 (31%)
HPId
Low 46 31 (67%) 0.04 30 (65%) NS 23 (50%) NS 21 (46%) NS
High 51 23 (45%) 28 (55%) 23 (45%) 16 (31%)
NS Statistically not significant
aTwo-sided p values obtained by Fisher's exact test, which are considered to be significant if p<0.05, of marginal significance if 0.05≤ p<0.1,
and not significant if p≥0.1
bCIS (score Hep Par 1 staining+score CD10 canalicular staining−score CD10 cytoplasmic staining)
cPercentages are computed with regard to number of patients for a given factor category
dHPI according to Lauwers et al. [23]
Fig. 2 Correlation between
Edmondson and Steiner’s tumor
grade and immunohistochemical
scores: Hep Par 1 expression is
significantly decreased in grades
3 and 4 carcinomas (a).
CD10can expression is highly
decreased in grade 4 tumors (b).
Combined immunohistochemi-
cal score (CIS=Hep Par 1 score +
CD10can score − CD10cyt
score) shows a progressive de-
crease with increasing tumor
grade (c). p values were deter-
mined using Kruskal–Wallis
tests
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there was only a weak association between CD10cyt labeling
and overall survival in the whole cohort (p=0.2) and in the
subgroup of patients with partial resection (p=0.3). Patients
with CD10cyt positive tumors tended to have a reduced
overall survival as compared to patients with CD10cyt
negative tumors.
Table 2 Univariate analysis of the immunohistochemical factors
All patients Only patients treated by partial resection
Immunohistochemical
score
Number of
patients (censored)
Median survival
time (month)
95% CI
(month)
p valuesa Number of
patients (censored)
Median survival
time (month)
95% CI
(month)
p values
Hep Par 1
<3 43 (9) 15 9–21 0.0005 36 (6) 14 6–22 0.03
=3 54 (32) >100 – 36 (18) 33 6–60
CD10 canalicular staining
<2 39 (11) 17 7–27 0.02 31 (7) 16 6–26 0.09
≥2 58 (30) 54 24–84 41 (17) 28 4–52
CD10 cytoplasmic staining
<1 51 (24) 31 17–45 NS 34 (13) 27 10–44 NS
≥1 46 (17) 27 11–43 38 (11) 16 0–33
CISb
<4 60 (16) 17 9–25 0.0004 48 (9) 16 13–19 0.004
≥4 37 (25) >80 – 24 (15) >80
NS Statistically not significant
aTwo-sided p values obtained by log-rank test, which are considered to be significant if p<0.05, of marginal significance if 0.05≤ p<0.1, and
not significant if p≥0.1
bCIS (score Hep Par 1 staining + score CD10 canalicular staining − score CD10 cytoplasmic staining)
Fig. 3 Overall survival curves
of all 97 patients who underwent
either partial hepatectomy with
curative intent or total hepatec-
tomy with liver transplantation
according to Hep Par 1 score
(a), CD10can score (b), com-
bined immunohistochemical
score (CIS=Hep Par 1 score +
CD10can score − CD10cyt
score) (c). Overall survival
curves of the subgroup of 72
patients who underwent partial
hepatectomy with curative intent
according to combined immu-
nohistochemical score (d).
p values were determined
using the log-rank test
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To be able to use these immunohistochemical parameters
in a routine clinical setting, they were combined into a
simple score according to the following formula: CIS =
Hep Par 1 score + CD10can score − CD10cyt score. On
univariate analysis, there was a highly significant correla-
tion between CIS and overall survival in both the whole
cohort (p=0.0004) and the patients with partial liver
resection (p=0.01). In the whole study population, patients
with a CIS ≥4 survived more than 80 months whereas the
median overall survival of the others was only 17 months
(Fig. 3c). Similar median overall survival times were found
in the subgroup of partially resected patients (80 vs.
16 months; Fig. 3d).
Multivariate survival analysis
Multivariate analysis was performed using several Cox
regression models with a limited number of covariates,
because the number of outcome events did not allow the
evaluation of all pertinent parameters at once. Prognostic
variables which had been at least marginally significant
(log-rank test <0.1) in univariate analysis (tumor size,
stage, multifocality, and grade as well as MVI, HPI, and
surgical margins; Table 3) were further analyzed in various
Cox regression models using backward selection with
p<0.05 as the exit criterion. Following clinicopathological
parameters had no impact on survival in univariate analysis
and were not further assessed in multivariate models:
preoperative transaminase levels and cholestatic param-
eters, viral hepatitis B and C, alcohol-related liver disease,
cigarette smoking, sex, age, and tumor growth pattern.
Although not statistically significant on univariate analysis
in our series, concomitant liver cirrhosis and preoperative
AFP levels were included in a multivariate model because
they are well-known prognostic markers.
In the models including only clinicopathological param-
eters, the retained prognostic factors were tumor multifo-
cality and size in the whole cohort and tumor multifocality
and grade in the subgroup of patients with liver resection
(model 1 from Table 4).
In the model including Hep Par 1, CD10can, and
CD10cyt, all three immunohistochemical parameters were
retained, and the regression coefficients (whole cohort)
were 0.72, 0.77, and 0.78 for Hep Par 1, CD10can, and
CD10cyt, respectively (model 2 from Table 4). Taken
Table 3 Univariate analysis of the clinicopathological factors
All patients Only patients treated by partial resection
Factora Number of
patients (censored)
Median survival
time (month)
95% CI
(month)
p valuesb Number of
patients (censored)
Median survival
time (month)
95% CI
(month)
p values
Tumor size
≤5 cm 58 (33) 54 6–102 0.0006 37 (17) 33 17–49 0.07
>5 cm 39 (8) 14 9–19 35 (7) 14 8–20
Tumor stage (TNM)
I+II 33 (21) 95 2–188 0.001 22 (12) 42 26–58 0.06
III 29 (11) 27 14–40 23 (7) 21 4–38
IV 35 (9) 14 9–19 27 (5) 13 6–20
Tumor multifocality
solitary 43 (25) 95 5–185 0.001 31 (15) 33 21–45 0.007
multiple 54 (16) 14 9–19 41 (9) 13 7–19
Edmondson and Steiner’s grade
1 20 (13) 43 – 0.04 16 (10) 43 20–66 0.07
2 44 (17) 27 12–42 31 (7) 15 5–25
3+4 33 (11) 16 6–26 25 (7) 16 11–21
MVI
Absent 62 (31) 42 27–57 0.04 46 (18) 30 22–38 0.2
Present 35 (10) 15 8–21 26 (6) 10 5–15
HPIc
Low 46 (25) 54 8–100 0.03 34 (15) 42 18–66 0.1
High 51 (16) 16 13–19 38 (9) 15 11–18
Surgical margins
Negative 78 (37) 33 17–49 0.05 56 (22) 30 18–42 0.01
Positive 14 (4) 9 7–11 11 (2) 9 6–12
aFollowing factors did not show a significant impact on survival (p>0.2) and are omitted from this table for simplicity: concomitant liver
cirrhosis, etiology of underlying liver pathology (alcohol, hepatitis B, and hepatitis C), as well as preoperative AFP levels, cytolytic, and
cholestatic parameters
bTwo-sided p values obtained by log-rank test, which are considered to be significant if p<0.05, of marginal significance if 0.05≤ p<0.1 and
NS if p≥0.1
cHPI was computed according to Lauwers et al. [23]
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together with the selected clinicopathological parameters,
Hep Par 1 and CD10can were retained in the models
(models 3 and 4 from Table 4, respectively). However, p
values and relative risk were lower for Hep Par 1 and
CD10can alone as compared to CIS (see below).
All models testing CIS in conjunction with different
clinicopathological parameters resulted in the retention of
the same final variables. Models 5 and 6 from Table 4 are
representative examples. CIS was the most significant prog-
nostic factor in both the complete cohort (p=0.001) and the
subgroup of liver-resected patients (p=0,004). Patients with
a CIS <4, as compared to those with a CIS ≥4, had a 3.5-
fold (95% CI 1.7–7.3) and a 3.7-fold (95% CI 1.5–8.9)
increased risk of death in the whole cohort and the sub-
group of patients with liver resection, respectively. In the
model of the whole cohort, tumor multifocality was the
only additional prognostic factor (p=0.005): patients with
multifocal HCC had a 2.4-fold (95% CI 1.3 to 4.3) in-
creased risk of death as compared to those with solitary
tumors. In the model of patients with liver resection only,
tumor multifocality (p=0.02) and Edmondson and Steiner’s
grade (p=0.04) were retained in addition to CIS.
Discussion
Hepatocellular carcinoma is one of the most common
malignant tumors worldwide that has typically poor prog-
nosis regardless of the treatment, and its incidence and
mortality are on the rise in Western nations [14]. Clinicians
need prognostic indicators to inform their patients and to
stratify them for eventual additional therapy. The present
study of Hep Par 1 and CD10 expression in HCC by
immunohistochemistry was undertaken to identify new
prognostic markers for patients treated with curative intent
by partial or total hepatectomy, the latter with liver
transplantation.
In our study population, strong cytoplasmic Hep Par 1
and CD10can expression, as well as absent CD10cyt
labeling, were correlated with longer overall survival. To
obtain a practical algorithm for clinical use, these three
immunohistochemical parameters were combined into a
single immunohistochemical score, which showed a highly
significant correlation with overall survival. Multivariate
analysis proved CIS to be the most important independent
prognostic factor, followed by tumor multifocality and
Edmondson and Steiner’s grade. Furthermore, CIS is su-
perior to Hep Par 1 or CD10 scores alone with regard to
risk assessment. To our knowledge, this is the first study to
demonstrate the prognostic value of these markers, although
their use is well documented in establishing the diagnosis
of HCC [5, 7, 8, 38]. CIS was also the most significant
prognostic indicator in the subgroup of patients treated by
partial hepatectomy, which excludes the possibility of a bias
due to the type of surgery. Unfortunately, the limited number
of patients treated by total hepatectomy and the limited
duration of follow-up precluded analysis of this subgroup.
A future study is planned to examine in detail the prog-
nostic value of Hep Par 1 and CD10 in this group of patients.
Prognostic indices are usually derived from the final Cox
regression model by using the regression coefficients as
weights for the corresponding scores [6]. However, we
preferred a more simple prognostic index based on a weight
of +1 for Hep Par 1 and CD10can and a weight of −1 for
CD10cyt scores for two reasons. First, its determination is
simple enough to be applicable in a routine setting. Second,
as shown by the Cox model, including these three pa-
rameters, the absolute value of their regression coefficients
is roughly the same (about 0.7), which justifies a posteriori
such a score. Interestingly, several parameters, such as
TNM stage, tumor size, MVI, HPI, and surgical resection
margins, which are known in the literature to be of prog-
nostic significance, were not retained in our Cox regression
models. This can be explained by correlation of the im-
munohistochemical variables with these clinicopathologi-
cal parameters, as shown in Table 1 for tumor size and
grade, MVI and HPI. Second, tumor multifocality, which
remains significant in our multivariate models, contains
partly the same prognostic information as TNM stage,
which is based on the former.
The precise biological mechanisms underlying the im-
pact of Hep Par 1 and CD10 expression on prognosis have
yet to be identified. It might be linked to the fact that Hep
Par 1 and CD10can expressions are indicators of a high
degree of differentiation. Indeed, in our series, there was a
correlation between the expression of these markers and
histological grade. These findings are in line with several
reports in the literature [5, 8, 21, 39]. Another argument in
favor of this hypothesis is the fact that poorly differentiated
HCC are known to be devoid of bile canaliculi [5, 7].
Therefore, these tumors are frequently unreactive with
antibodies directed against CD10 which is a neutral endo-
peptidase located at the luminal aspects of bile canaliculi.
To explain the intriguing feature of CD10cyt labeling in the
less differentiated and more aggressive tumors, one might
also speculate that redistribution of CD10 from the cell
surface to the cytoplasm is an indirect sign of lost cell
polarity, which is one of the hallmarks of cancer [35]. This
redistribution might be the consequence of aberrant gly-
cosylation, alternative splicing, or a truncating mutation of
the CD10 gene [33, 36].
In conclusion, our study identifies Hep Par 1 and CD10
expression as the most informative predictors of overall
survival in HCC patients treated by partial liver resection
with curative intent. Introduction of these parameters in
clinical decision making, however, requires confirmation
of these preliminary findings in another population of HCC
patients. Whether these findings apply also to patients
treated with total hepatectomy and liver transplantation as
suggested by the present work will require further studies.
Future prospective studies are also necessary to determine
whether or not the CIS can be helpful for the choice of
additional treatment and prediction of prognosis in patients
who are beyond curative surgery.
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